Head honcho

Houston biopharmaceutical company brings on new CEO to grow company

A Houston biotech company has a new CEO and is ready for growth. Getty Images

With a veteran of the biopharmaceutical industry now aboard as its CEO and an executive at pharmaceutical giant AstraZeneca now serving on its board, Houston-based biopharmaceutical company Pulmotect Inc. is poised for progress.

In September, Dr. Colin Broom joined Pulmotect as CEO. He previously was CEO of Ireland-based Nabriva Therapeutics plc, a biopharmaceutical company that went public in 2015. During Broom's tenure at Nabriva, he helped develop the recently approved drug Xenleta, which treats bacterial pneumonia. Before that, he was chief scientific officer at Pennsylvania-based pharmaceutical company ViroPharma Inc., which Massachusetts-based Shire plc purchased for $4.2 billion in 2014.

Broom's hiring came on the heels of Kumar Srinivasan being named to Pulmotect's board of directors. Srinivasan is vice president of United Kingdom-based AstraZeneca and is its global head of business development and licensing for biopharmaceuticals R&D.

Researchers at MD Anderson Cancer Center and Texas A&M University invented Pulmotect's main product, PUL-042, which holds patents in nine countries. Pulmotect, founded in 2007, emerged from Houston's Fannin Innovation Studio, which nurtures early stage companies in the life sciences sector.

"Attracting such a highly regarded and proven CEO as Colin is a clear signal of the power and potential of Pulmotect's development program," Pulmotect's executive chairman, Leo Linbeck III, founder and chairman of Fannin, says in a release. "Under his leadership, I'm confident that we will advance our technology further into the clinic and closer to the marketplace. His addition is a real game-changer for the company."

Both Broom and Srinivasan are focusing on clinical trials for Pulmotect's PUL-042 product, an inhaled therapy that holds the potential to prevent or treat respiratory infections caused by bacteria, viruses, or fungi. The current Phase 2 trial is evaluating the effectiveness of PUL-042 in treating patients with mild chronic obstructive pulmonary disease (COPD) who've been exposed to a respiratory virus. The current trial is supposed to be followed by additional Phase 2 trials.

COPD, which affects 30 million Americans, is the No. 3 cause of death in the U.S., according to the COPD Foundation. Pulmotect says 40 percent of COPD-related costs could be avoided by preventing complications and hospitalizations, which typically result from COPD problems triggered by a bacterial or viral infection. PUL-042 could substantially decrease those complications, the company says.

Pulmotect seeks to gear PUL-042 toward patients with cancer who are undergoing chemotherapy, as their weakened immunity makes them highly susceptible to pneumonia, Broom says. If the product proves effective with those patients, then people at risk of developing respiratory infections also might benefit from it, including COPD patients and flu patients, he says.

To date, Pulmotect has raised more than $28 million in funding. That includes about $18 million in research grants, including a $7 million grant from the Cancer Prevention and Research Institute of Texas, as well as seven grants from the Small Business Innovation Research program.

Two of Pulmotect's three full-time employees work in Houston, and a team of consultants supports their work, Broom says. A small number of employees might be added during the current Phase 2 trial. Hiring would need to be ramped up if the Phase 2 trial demonstrates that PUL-042 works, he says.

Trending News

Building Houston

 
 

Free mental health care, local COVID-19 testing, and a new great to fund an ongoing study — here's your latest roundup of research news. Image via Getty Images

As Houston heads toward the end of summer with no major vaccine or treatment confirmed for COVID-19, local research institutions are still hard at work on various coronavirus-focused innovations.

Free mental health care, local COVID-19 testing, and a new great to fund an ongoing study — here's your latest roundup of research news.

Baylor College of Medicine genomics team to partner for local COVID-19 testing

Houston millionaire to start biotech accelerator for companies focusing on regenerative medicine

Two departments at BCM are working with the county on COVID-19 testing. Getty Images

Two Baylor College of Medicine institutions have teamed up to aid in local COVID-19 testing. The Human Genome Sequencing Center and the Alkek Center for Metagenomics and Microbiome Research — under the leadership of BCM — are partnering with local public health departments to provide polymerase chain reaction testing of COVID-19 samples, according to a news release from BCM.

"We are pleased to work with the outstanding local government groups in this critical public health effort," says Dr. Richard Gibbs, director of the HGSC and Wofford Cain chair and professor of molecular and human genetics at Baylor, in the release. "We are proud of the tireless determination and expertise of our centers and college staff that enabled the rapid development of this robust testing capacity to serve the greater Houston community."

Baylor is among the testing providers for Harris County Public Health, and people can receive testing following a pre-screening questionnaire online.

"We are fortunate to have Baylor College of Medicine as a close partner during the COVID-19 pandemic," says Dr. Umair Shah, executive director of Harris County Public Health, in the release. "This is a challenging time for our community and as the need for increased testing capacity and getting results to residents faster has grown, Baylor has risen to the occasion. There are countless unsung heroes across Harris County who have stepped up to the plate during this pandemic and Baylor College of Medicine is one of them."

COVID-19 testing samples are collected from testing sites and delivered to the Alkek Center. After isolating the virus, genomic material is extracted and sent to the HGSC to quantitative reverse transcription PCR testing. Should the sample's RNA sequence match the virus, then it is positive for COVID-19. The sequencing must test positive three times to be considered overall positive.

Results are returned within 48 hours, and the lab has a capacity of more than 1,000 samples a day. Since May, the team has tested over 30,000 samples.

"We knew we had all the pieces to stand up a testing center fast – large scale clinical sequencing, experts in virology and molecular biology, and a secure way to return results to patients," says Ginger Metcalf, Human Genome Sequencing Center Director of Project Development, in the release. "We are also fortunate to have such great partners at Harris County Public Health, who have done an amazing job of gathering, tracking and delivering samples, especially for the most at-risk members of our community."

National Science Foundation renews Rice University funding amid pandemic

José Onuchic (left) and Peter Wolynes are co-directors of the Center for Theoretical Biological Physics at Rice University. Photo by Jeff Fitlow/Rice University

Rice University's Center for Theoretical Biological Physics has been granted a five-year extension from the National Science Foundation. The grant for $12.9 million will aid in continuing the CTBP's work at the intersection of biology and physics.

The center — which was founded in 2001 at the University of California, San Diego, before moving to Rice in 2011 — is led by Peter Wolynes and José Onuchic.

"We have four major areas at the center," Onuchic says in a news release. "The first is in chromatin theory and modeling, developing the underlying mathematical theory to explain the nucleus of the cell — what Peter calls the 'new nuclear physics.' The second is to test ideas based on the data being created by experimentalists. The third is to understand information processing by gene networks in general, with some applications related to metabolism in cancer. The fourth is to study the cytoskeleton and molecular motors. And the synergy between all of these areas is very important."

Onuchic adds that an upcoming donation of a supercomputer by AMD will help the center's ongoing research into COVID-19 and four institutions — Rice, Northeastern, Baylor College of Medicine and the University of Houston — are working collaboratively on the study,

"We're all set to move on doing major COVID-related molecular simulations on day one," he says in the release. "The full functioning of a center requires a synergy of participation. Rice is the main player with people from multiple departments, but Baylor, Northeastern and Houston play critical roles."

University of Houston offers free mental health therapy for restaurant workers

Texas restaurant workers can get free mental health care from a UH initiative. Photo via Elle Hughes/Pexels

Through a collaboration with Southern Smoke and Mental Health America of Greater Houston, the University of Houston Clinical Psychology program launched a a free mental health care program for Texas-based food and beverage employees and their children.

"During normal times this is a high stress industry where people work very hard in environments where they are just blowing and going all the time," says John P. Vincent, professor of psychology and director of the UH Center for Forensic Psychology, in a news release.

The program has 14 graduate students who converse with a total of 30 patients and meet weekly with supervisors at UH.

"This opportunity allows our clinical program to reach people in the community who usually don't have access to mental health services," says Carla Sharp, professor of psychology and director of clinical training, in the release.

For restaurant industry workers looking for help and care, they can visit the Mental Health Services page on Southern Smoke's website.

According to Vincent, this is just the beginning.

"We're discussing it," says Vincent in the release. "But as far as I'm concerned it can just keep going and going."

Trending News